🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCagriSema (amylin + semaglutide) — my results so far Page 3

CagriSema (amylin + semaglutide) — my results so far

Dr.NutriCornell Wed, Apr 1, 2026 at 9:59 AM 31 replies 1,170 viewsPage 3 of 7
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Apr 1, 2026 at 7:18 PM#11
Dr.AddMedPHL said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

44 19TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 41 others
Reply Quote Save Share Report
TomTeleRx
Member
189
678
Feb 2025
Delaware
Apr 1, 2026 at 10:25 PM#12
SarahChen_PharmD said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Saving this. It is the first explanation that did not require me to already understand it.

43 18bri_stats, pete_manc_UK, anna.melb_AU and 40 others
Reply Quote Save Share Report
B12Beth
Member
289
890
Oct 2024
Maryland
Apr 2, 2026 at 1:32 AM#13
Dr.AddMedPHL said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

42 17DanielChem_CHI, marco_milano, pam_columbus and 39 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Apr 2, 2026 at 4:39 AM#14

The figures, for anyone assembling their own picture. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

41 16Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 38 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Apr 2, 2026 at 7:46 AM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Tagging this one for the weekly digest.

Last edited: Apr 2, 2026 at 9:46 AM
40 15PurityPaulOR, MaxMetOK, MounjBrad and 37 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register